NKTR vs REGN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. NKTR and REGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined NKTR and REGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Nektar Therapeutics is a San Francisco based, Nasdaq-listed clinical-stage biopharmaceutical company whose pipeline is anchored by rezpegaldesleukin (rezpeg), a first-in-class biologic designed to stimulate and expand regulatory T cells to restore immune balance. Nektar regained full rights to the molecule from Eli Lilly and is developing it across immuno-dermatology indications, with a Phase 2b program in moderate-to-severe atopic dermatitis (REZOLVE-AD, 393 patients), a Phase 2b program in severe-to-very-severe alopecia areata (REZOLVE-AA), and a Phase 2 study in type 1 diabetes. In February 2026 the company reported maintenance data from REZOLVE-AD showing durable and new responses on key disease measures with both monthly and quarterly dosing, and rezpeg holds FDA Fast Track designation in atopic dermatitis.

Full NKTR guide

Regeneron makes money primarily through two large franchises. Dupixent, an anti-inflammatory antibody used for eczema, asthma, COPD, and other conditions, is developed and commercialized in collaboration with Sanofi, and Regeneron records its share through Sanofi collaboration revenue (about $1.6 billion in Q1 2026, up roughly 36%). Eylea and the higher-dose Eylea HD treat retinal diseases such as wet age-related macular degeneration and diabetic eye disease, generating combined U.S. net product sales of about $941 million in Q1 2026, with Eylea HD now roughly half of that mix. Libtayo in oncology and a pipeline of nearly 50 clinical candidates round out the revenue base.

Full REGN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• NKTR drivers: Rezpegaldesleukin in atopic dermatitis; Alopecia areata expansion.
• REGN drivers: Dupixent keeps compounding; A deep, diversified pipeline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Nektar is pre-commercial, so it has no approved product revenue and continues to post operating losses funded by its balance sheet. For REGN, the clearest risk is Eylea biosimilar erosion.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick NKTR if you believe its drivers more; REGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the NKTR and REGN guides.

NKTR. As a clinical-stage biopharma, Nektar carries no meaningful earnings, so traditional profit multiples do not apply and its value reflects the perceived probability and size of rezpegaldesleukin's opportunity. The ~$1B cash position is a large fraction of the ~$2.5B market cap, meaning much of the equity value is tied to pipeline expectations rather than current operations.

REGN. Figures are approximate and tied to the asOf date; verify current numbers with a live quote before acting. Regeneron reported about 19% revenue growth and adjusted EPS of roughly $9.47 in Q1 2026, beating estimates, and authorized an additional $3 billion buyback. The mid-teens P/E reflects the market weighing strong Dupixent growth against expected Eylea biosimilar erosion.

Headline figures (approximate, July 2026): NKTR shows share price ~$74 (early July 2026), market cap ~$2.5B, q1 2026 revenue ~$10.9M, q1 2026 net loss ~$44.9M (~$1.82/share); REGN shows total revenue (ttm, approx) ~$14 billion, q1 2026 total revenue ~$3.6 billion (up ~19% YoY), dupixent global net sales (q1 2026) ~$4.9 billion (up ~31%), eylea + eylea hd u.s. net sales (q1 2026) ~$941 million combined.

NKTR and REGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined NKTR and REGN exposure against your real portfolio. It is not an investment adviser.